Analysis of Influencing Factors of Hp Eradication and Effect of Bifidobacterium on Hp Re-eradication / 胃肠病学

ABSTRACT

Background:Antibiotic resistance rate of Helicobacter pylori (Hp) has increased year by year,which leads to the lowering Hp eradication rate,therefore,it is emergent to find an effective Hp eradication regimen.Aims:To explore the effect of influencing factors on Hp eradication rate,and to investigate the clinical effect of Bifidobacterium on re-eradication of Hp.Methods:A total of 203 Hp-positive patients with gastric diseases diagnosed by gastroscopy and pathology were enrolled.All the patients were given standard triple regimen for 2 weeks,Hp infection was re-examined 4 weeks after treatment.Fifty patients with Hp eradication failure were divided into two groups,patients in experimental group were given Bifidobacterium followed by quadruple therapy,patients in control group were given quadruple therapy directly.Effects of gender,age,gastroscopic diagnosis,pathological diagnosis and different regimens on Hp eradication rate were analyzed,and effect of Bifidobacterium on re-eradication of Hp was evaluated.Results:No significant difference in Hp eradication rate was found between male and female patients (P =0.740).Hp eradication rate decreased with the increase of age,however,the difference was not statistically significant (P =0.872).No significant differences in Hp eradication rate were found between different eradication regimens,gastroscopic diagnosis,and pathological diagnosis (P ＞ 0.05).Reeradication rate of Hp in Bifidobacterium group was higher than that in control group,but the difference was not statistically significant (88.0％ vs.72.0％,P =0.289).Conclusions:The effects of gender,age,gastroscopic diagnosis and pathological diagnosis,different eradication regimens on Hp eradication rate are not statistically different.However,Hp eradication rate is decreased with the increase of age.Hp eradication rate is relatively high in patients with chronic atrophic gastritis.Bifidobacterium can not increase the re-eradication rate in patients with the failure of first time Hp eradication therapy.